I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail, in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alex

22313-1450, on the date shown below.

Docket No.: 554792000500

(PATENT)

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of: Gregory N. BEATCH et al.

Application No.: 09/913,373

Group Art Unit: 1626

Filed: January 28, 2002

Examiner: S. Wright

For: CYCLOALKYL AMINE COMPOUNDS AND

**USES THEREOF** 

## REVOCATION OF POWER OF ATTORNEY AND NEW POWER OF ATTORNEY

MAIL STOP: ART UNIT 1626 Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Dear Sir:

TECH CENTER 1000 COCO

The undersigned having, on or about September 15, 2003, appointed Michael R. Ward of MORRISON & FOERSTER, LLP, as our attorney to prosecute an application for Letters Patent, which application was filed on January 28, 2002, for an invention entitled CYCLOALKYL AMINE COMPOUNDS AND USES THEREOF, Application No. 09/913,373, hereby revokes the Power of Attorney then given, and hereby appoints the following attorneys and/or agents to prosecute this application and transact all business in the U.S. Patent and Trademark Office connected herewith:

Lisa A. Amii	48,199	Carol M. Gruppi	37,341	James J. Mullen, III	44,957
Randolph Ted Apple	36,429	Alicia J. Hager	44,140	Kate H. Murashige	29,959
Mehran Arjomand	48,231	Johney U. Han	45,565	Martin Noonen	44,264
Shantanu Basu	43,318	Laurie L. Hill	51,804	Catherine M. Polizzi	40,130
Vincent J. Belusko	30,820	Douglas G. Hodder	41,840	Philip D. Reilly	41,415
Jonathan Bockman	45,640	Alan S. Hodes	38,185	James Remenick	36,902
Kimberly A. Bolin	44,546	Charles D. Holland	35,196	Robert A. Saltzberg	36,910
Barry E. Bretschneider	28,055	Arthur S. Hsieh	48,247	Robert E. Scheid	42,126

Nicholas S. Buffinger	39,124	Jill A. Jacobson	40,030	Debra A. Shetka	33,309
Robert K. Cerpa	39,933	Wayne C. Jaeschke, Jr.	38,503	Rebecca Shortle	47,083
Alex Chartove	31,942	Parisa Jorjani	46,813	J. David Smith	39,839
Peng Chen	43,543	Ararat Kapouytian	40,044	Kevin R. Spivak	43,148
Thomas E. Ciotti	21,013	Richard C. Kim	40,046	Shannon Thomas	52,285
Cara M. Coburn	46,631	Cameron A. King	41,897	Thomas L. Treffert	48,279
Raj S. Dave'	42,465	Norman R. Klivans	33,003	Brenda J. Wallach	45,193
Peter J. Davis	36,119	Glenn M. Kubota	44,197	Michael R. Ward	38,651
David L. Devernoe	50,128	Kawai Lau	44,461	E. Thomas Wheelock	28,825
Scott W. Doyle	39,176	Katherine D. Lee	44,865	Todd W. Wight	45,218
Stephen C. Durant	31,506	Otis Littlefield	48,751	Eric H. Witt	44,408
Christopher B. Eide	48,375	Hugh H. Matsubayashi	43,779	Timothy A. Worrall	54,552
Carolyn A. Favorito	39,183	Michael J. Mauriel	44,226	Bryan H. Wyman	48,049

2

Docket No.: 554792000500

44,415

44,417

46,332

52,395

#### Address all communications to:

28,600

40,614

43,636

33,888

47,608

Mika Mayer

Robert S. McArthur

Gladys H. Monroy

Scott C. Moore

Philip A. Morin

Michael R. Ward MORRISON & FOERSTER LLP 425 Market Street San Francisco, California 94105 (415) 268-7000

For: CARDIOME PHARMA CORP.

Alan M. Ezrin, **P**h.D.

Chief Scientific Officer

Application No.: 09/913,373

Dated: 15 Splendie 200

47,777

45,674

32,430

52,047

45,926

David Yang

Peter J. Yim

Jie Zhou

Karen Zachow

sf-1567981

David L. Fehrman

Hector G. Gallegos

Debra J. Glaister

Bruce D. Grant

Deborah S. Gladstein

Attorney Docket: 554792000500



# **STATEMENT UNDER 37 CFR 3.73(b)**

Applicant	t/Patent Owner:	Gregory N. BEATCH, et a	<u>I.</u>					
Application	on No./Patent No.:	09/913,373	Filed/Issue Date:	January 28, 2002				
Entitled: CYCLOALKYL AMINE COMPOUNDS AND USES THEREOF								
	CARDIOME PHA	RMA CORP. , a	cor	poration on, partnership, university, government				
	(Name of Ass	signee)	Type of Assignee, e.g., corporati ag	ion, partnership, university, government ency, etc.				
states tha	at it is:							
1. X	the assignee of the	ne entire right, title, and inte	rest; or					
2. an assignee of less than the entire right, title and interest.  The extent (by, percentage) of its ownership interest is %								
in the pat	tent application/pat	ent identified above by virtu	e of either:	$\mathcal{P}_{\lambda}$				
OR	was recorded in the Frame 084	e United States Patent and 0 , or for which a copy	Trademark Office at Reel thereof is attached.	CH CENT 26				
	A chain of title from assignee as shown	the inventor(s), of the pate below:	nt application/patent iden	tified above, to the content				
	1. From:		To:					
		vas recorded in the United S						
	Reel	, Frame	, or for which a copy	thereof is attached.				
:	2. From:		To:					
		vas recorded in the United S						
	Reel	, Frame	, or for which a copy	thereor is attached.				
;	3. From:		To:					
		vas recorded in the United S						
	Reel	, Frame	, or for which a copy	thereof is attached.				
ļ	[ ] Additional documents in the chain of title are listed on a supplemental sheet.							
·	Copies of assignments or other documents in the chain of title are attached.  [NOTE: A separate copy (i.e., the original assignment document or a true copy of the original document) must be submitted to Assignment Division in accordance with 37 CFR Part 3, if the assignment is to be recorded in the records of the USPTO. See MPEP 302.08]							
The unde	ersigned (whose titl	e is supplied below) is autho	orized to act on behalf of t	the assignee.				
September 19, 2003				I R. Ward				
	Date		Typed or p	printed name				
				nature				
			3					
	Attorney for Assignee Title							

Docket No.: PF-0467-2 DIV

Certificate of Mailing

Thereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Mail Stop: Non-Fee Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on September 19, 2003

#### IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

Bandman et al.

HUMAN BETA-ALANINE-PYRUVATE AMINOTRANSFERASE

Serial No.:

10/159,924

Filing Date:

May 31, 2002

Examiner:

Steadman, D.

Group Art Unit:

1652

Mail Stop: Non-Fee Amendment

Commissioner for Patents

P.O. Box 1450

Alexandria, VA 22313-1450

ASSOCIATE POWER OF ATTORNEY

Sir:

TECH CENTER 2 6 I hereby appoint the following patent attorneys/agents, whose post office address is 3160 Porter Drive, Palo Alto, California 94304, as associate attorneys/agents in the above-entitled application, to prosecute this application, to make alterations and amendments therein, and to transact all business in the Patent and Trademark Office connected therewith:

Sharmila Pandharipande

Limited Recognition (37 C.F.R. 10.9 (b)) attached

Please continue to address all future communications to:

Legal Department **Incyte Corporation** 3160 Porter Drive Palo Alto, California 94304

Respectfully submitted,

INCYTE CORPORATION

Date: September 19, 2003

Richard C. Ekstrom

Reg. No. 37,027

Direct Dial Telephone: (650) 843-7352

Customer No.: 27904 3160 Porter Drive

Palo Alto, California 94304

Phone: (650) 855-0555 or Fax: (650) 845-4166

114286 1 10/159,924



# BEFORE THE OFFICE OF ENROLLMENT AND DISCIPLINE UNITED STATES PATENT AND TRADEMARK OFFICE

### LIMITED RECOGNITION UNDER 37 CFR § 10.9(b)

Sharmila Pandharipande is hereby given limited recognition under 37 CFR § 10.9(b) as an employee of Incyte Genomics, Inc. to prepare and prosecute patent applications wherein the assignee of record of the entire interest is Incyte Genomics, Inc. This limited recognition shall expire on the date appearing below, or when whichever of the following events first occurs prior to the date appearing below: (i) Sharmila Pandharipande ceases to lawfully reside in the United States, (ii) Sharmila Pandharipande's employment with Incyte Genomics, Inc. ceases or is terminated, or (iii) Sharmila Pandharipande ceases to remain or reside in the United States on a H1B1 visa.

This document constitutes proof of such recognition. The original of this document is on file in the Office of Enrollment and Discipline of the United States Patent and Trademark Office.

Expires: February 17, 2004

Harry I. Moatz

Director of Enrollment and Discipline